Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing
Glofitamab and epcoritamab are CD3xCD20 bispecific antibodies licensed for relapsed/refractory large B cell lymphoma (RR LBCL), yet real-world data are limited. Data were collected from 332 patients (219 glofitamab, 113 epcoritamab) across 34 UK centres (November 2023-May 2025). This high-risk cohort had median 2 prior lines of treatment; 179 (55%) primary refractory disease; 81 (25%) ECOG ≥2; 152 (50%) prior Chimeric Antigen Receptor T-cell therapy; and 232 (78%) pivotal-trial ineligible. 7 patients died before treatment initiation, 1 patient was yet to start treatment, of 324 treated patients, 28% had cytokine release syndrome (CRS), predominately grade 1/2 (82/90). Overall response rate (ORR) and complete response rate (CRR) were 43% and 24%, respectively, while for trialeligible patients the CRR was 43%. At a median 10.0 months follow-up (IQR 5.3-15.0), median progression-free survival (PFS) was 3.1 months (95% confidence interval [CI], 2.5-4.2), median overall survival (OS) was 6.9 months (95% CI, 4.9-10.8). For patients not completing cycle 2, 6-month OS was 4% (95% CI 1-11%). Median duration of complete response was not reached. Refractoriness to prior line of treatment (HR 2.89, 95% CI 1.73-4.81, p=0.007), elevated LDH (HR 2.62, 95% CI 1.74-3.93. p=0.001), bendamustine exposure within 6 months (HR 1.62, 95% CI 1.14-2.30, p=0.007) and ECOG 1 (HR 2.70, 95% CI 1.52-4.79, p=0.001) or 2 (HR 6.49, 95% CI 3.47-12.01, p.
Authors
- Lisa Jeffers
- John Willan (ORCID: https://orcid.org/0000-0001-8700-2073)
- Matthew Wilson (ORCID: https://orcid.org/0009-0006-1231-0526)
- D. Lewis
- Anna Santarsieri (ORCID: https://orcid.org/0000-0002-4449-2196)
- Philippa Kelsey (ORCID: https://orcid.org/0000-0001-7486-3552)
- David Foldes (ORCID: https://orcid.org/0000-0003-3072-8214)
- Hwai Jing Hiew
- Sunil Iyengar (ORCID: https://orcid.org/0000-0003-4863-4160)
- Laura Dunning
- Rory McCulloch (ORCID: https://orcid.org/0000-0003-0090-7174)
- Susanna Mathew
- Andrea Kühnl (ORCID: https://orcid.org/0000-0002-4952-2550)
- Jeffery Smith
- Matthew Wells (ORCID: https://orcid.org/0000-0002-8683-3358)
- Andrew J. Davies (ORCID: https://orcid.org/0000-0002-2087-0885)
- Cristina M. Thiebaud (ORCID: https://orcid.org/0000-0003-2830-7592)
- Vismay Deshani
- Kushani Ediriwickrema (ORCID: https://orcid.org/0000-0002-0911-1589)
- Joanna Fawcett (ORCID: https://orcid.org/0000-0003-0767-3155)
- Dima El‐Sharkawi (ORCID: https://orcid.org/0000-0002-2752-5814)
- Christopher P. Fox (ORCID: https://orcid.org/0000-0002-6322-9254)
- Victoria Stables
- Harriet Ambrose
- Sudarshan Gurung
- Sanne Lugthart (ORCID: https://orcid.org/0000-0003-3007-8303)
- Mary Gleeson (ORCID: https://orcid.org/0000-0001-6915-9878)
- Henry Crosland
- Li Yuan Chan
- E B Haynes
- Graham Collins
- Angus Broom
- Gavin Preston
- Edward Kanfer
- Laura Oldham
- Janine Qasim (ORCID: https://orcid.org/0009-0009-7101-5676)
- Matthew Ahearne
- William Wilson
- Kim Linton
- Nimish Shah
- David Tucker
- Mary Owen
- Mahina Baloch
- Desmond Ojie
- William Townsend
- Kyaw Zin Dino Maw
- Tobias Menne
- Robert Osborn
- Jack Easton
- Rebecca Auer
- Caroline Besley
- Catherine Cox
- Jeff Lam
- George Follows
- Sridhar Chaganti
- Wendy Osborne
- Rishabh Motiwale
- Jane Norman
- Abigail Martin
- Sarah Lawless
- Pam McKay
- James Paterson
- Dominic Culligan
Institutions
- University College Hospital (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- University of Ulster (GB)
- University of Nottingham (GB)
- Maidstone and Tunbridge Wells NHS Trust (GB)
- Imperial College Healthcare NHS Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- University of Cambridge (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Norfolk and Norwich University Hospital (GB)
- Royal Cornwall Hospital Trust (GB)
- James Paget University Hospital (GB)
- Royal Cornwall Hospital (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Aberdeen Royal Infirmary (GB)
- Churchill Hospital (GB)
- Cancer Research UK (GB)
- At Bristol (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Manchester Royal Infirmary (GB)
- Gloucestershire Hospitals NHS Foundation Trust (GB)
- University Hospitals of Leicester NHS Trust (GB)
- Edinburgh Cancer Research (GB)
- Belfast City Hospital (GB)
- Frimley Health NHS Foundation Trust (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- South Tees Hospitals NHS Foundation Trust (GB)
- Manchester University NHS Foundation Trust (GB)
- Bridge University (SS)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Medway NHS Foundation Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- NIHR Southampton Biomedical Research Centre (GB)
- Kent and Medway NHS and Social Care Partnership Trust (GB)
- The Christie NHS Foundation Trust (GB)
- South Tyneside and Sunderland NHS Foundation Trust (GB)
- University Hospitals Plymouth NHS Trust (GB)
- University College London (GB)
Publication Details
- Journal
- Haematologica
- Published
- 2026-05-14
- DOI
- https://doi.org/10.3324/haematol.2026.300569
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00